Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IndegeneNSE:INDGN +0.17%51 14-Day RSI is 53.06 as of Sep. 14, 2026. GuruFocus rates NSE:INDGN with a GF Score™ of 51/100. The stock has 7 warning signs investors should review. Among 700 Healthcare Providers & Services companies, Indegene ranks worse than 71.29% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-14), Indegene's 14-Day RSI is 53.06.
The industry rank for Indegene's 14-Day RSI or its related term are showing as below:
NSE:INDGN's 14-Day RSI is ranked worse than 71.29% of 700
companies
in the Healthcare Providers & Services industry
Industry Median: 46.535
vs NSE:INDGN: 53.06
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Indegene 14-Day RSI Related Terms
NSE:INDGN vs VEEV, BTSG, TEM: 14-Day RSI Comparison
For the Health Information Services subindustry, Indegene's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indegene 14-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Indegene's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Indegene's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indegene (NSE:INDGN) has a 14-Day RSI of 53.06 as of Sep. 14, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Indegene and its competitors. According to the industry distribution chart, Indegene ranks #499 out of 700 companies in the Healthcare Providers & Services industry, placing it in the top 71.3%.
Is Indegene's 14-Day RSI too high?
Indegene's current 14-Day RSI is 53.06. The Healthcare Providers & Services industry median 14-Day RSI is 46.54. Indegene's value of 53.06 is 14% above this industry median. Based on the distribution chart, Indegene ranks #499 out of 700 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Indegene has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Indegene's 14-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Indegene ranks #499 out of 700 companies for 14-Day RSI. This places Indegene in the lower half of its industry. The industry median 14-Day RSI is 46.54. Indegene's value of 53.06 is 14% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Healthcare Providers & Services company?
The median 14-Day RSI among Healthcare Providers & Services companies is 46.54, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indegene's current 14-Day RSI of 53.06 is 14% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Indegene and its competitors. For the Healthcare Providers & Services industry, the median 14-Day RSI is 46.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indegene's current 14-Day RSI is 53.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indegene stock overvalued right now?
Indegene (NSE:INDGN) has a current 14-Day RSI of 53.06. The current 14-Day RSI is 53.06 and 14% above the Healthcare Providers & Services industry median of 46.54. Indegene's overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Indegene (NSE:INDGN), the current 14-Day RSI is 53.06 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.
51GF Score
Get the complete analysis for NSE:INDGN
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDGN has been successfully added to your 
